We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Cardiac Defibrillator Implanted Under Skin Much Safer for Patients

By HospiMedica International staff writers
Posted on 02 May 2022

Implantable cardioverter defibrillators (ICDs) improve survival of patients with heart conditions but can cause perioperative complications, including perforation of heart muscle or lungs, and blood clotting in veins. More...

Now, a new type of cardiac defibrillator has been found to significantly reduce major complications for patients.

The traditional defibrillator, the transvenous ICD (TV-ICD), features a lead (a flexible wire coated with insulation) placed in the heart or the heart’s network of blood vessels. Researchers at the Population Health Research Institute (PHRI, Hamilton, ON, Canada) have demonstrated that a different type of ICD - the subcutaneous ICD (S-ICD) – in which the lead is implanted under the skin, just below the patient’s armpit, and runs along the breastbone. The S-ICD does not come into contact with any blood vessels.

Their study found that by eliminating all intra-vascular and intra-cardiac components of the ICD, the S-ICD prevents most lead-related perioperative complications, including nearly all complications which can lead to death. The study followed patients for six months after their device was implanted in 544 patients (one-quarter female) at 14 clinical sites in Canada. Half of the patients were randomized to an S-ICD; the other half to a TV-ICD. The team found that S-ICD reduced the risk of lead-related complications by 92%. Younger patients are usually under-represented in ICD trials; ATLAS S-ICD included ICD-eligible patients 18 to 60 years old (average age of 49) who had a cardiogenetic syndrome or were at high risk for lead-related complications. Follow-up of participants of ATLAS S-ICD is ongoing.

“We need to increase the statistical power of the trial to assess the comparative rates of inappropriate shocks and failed appropriate shocks, as well as the impact of ICD type on tricuspid insufficiency and heart failure,” said PHRI Senior Scientist Jeff Healey.

Related Links:
PHRI 


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Ultrasound System
FUTUS LE
Morcellator
TCM 3000 BL
PACS Workstation
PaxeraView PRO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.